Novartis AG(NVS) Stock Research - Grey Stern Research

Novartis AG (NVS) Stock Analysis

$99.07 (-0.30%)

NVS Financial Performance


Use the table below to view Novartis AG's financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q3 - 2024

Metric Value Ranking among Peers
Price $99.07 -
52 Week Low $92.35 -
52 Week High $120.92 -
Market Cap $193.8 Billion 6/11
Gross Margin 74% 5/11
Profit Margin 25% 1/11
EBITDA margin 44% 2/11
Q3 - 2024 Revenue $12.8 Billion 7/11
Q3 - 2024 Earnings $3.2 Billion 2/11
Q3 - 2024 Free Cash Flow $6.0 Billion 3/11
Trailing 4 Quarters Revenue $48.9 Billion 7/11
Trailing 4 Quarters Earnings $17.6 Billion 1/11
Quarterly Earnings Growth 81% 3/11
Annual Earnings Growth 102% 2/11
Quarterly Revenue Growth 6% 8/11
Annual Revenue Growth -9% 10/11
Cash On Hand $13.6 Billion 2/11
Short Term Debt $6.8 Billion 3/11
Long Term Debt $23.8 Billion 7/11

Novartis AG Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare Novartis AG's metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 11.01 10/11
PS 3.96 7/11
PB 4.46 7/11
PC 14.24 9/11
Liabilities to Equity 1.39 7/11
ROA 0.17 1/11
ROE 0.41 3/11
Current Ratio 1.72 3/11
Quick Ratio 0.23 2/11
Long Term Debt to Equity 0.55 8/11
Debt to Equity 0.71 7/11
Burn Rate -25.40 11/11
Cash to Cap 0.07 1/11
CCR 1.87 5/11
EV to EBITDA 37.52 8/11
EV to Revenue 4.31 5/11

Company Details

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.

CEO: Joseph Jimenez

Website: https://www.novartis.com

Address: Lichtstrasse 35 Basel,

Exchange: New York Stock Exchange

Industry: Drug Manufacturers—General

Novartis AG Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to Novartis AG. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Pfizer Inc. PFE $148.6 Billion
Bristol-Myers Squibb Company BMY $113.4 Billion
Gilead Sciences, Inc. GILD $115.1 Billion
AbbVie Inc. ABBV $302.8 Billion
Merck & Co., Inc. MRK $253.2 Billion
Johnson & Johnson JNJ $349.0 Billion
GSK plc GSK $66.9 Billion
Eli Lilly and Company LLY $708.9 Billion
AstraZeneca PLC AZN $203.7 Billion
Sanofi SNY $123.2 Billion
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
NVS Income Statements
Quarter Year Revenue Earnings
Q3 2024 $ 12.8 Billion $3.2 Billion
Q2 2024 $ 12.5 Billion $3.2 Billion
Q1 2024 $ 11.8 Billion $2.7 Billion
Q4 2023 $ 11.8 Billion $8.5 Billion
Q3 2023 $ 12.1 Billion $1.8 Billion
Q2 2023 $ 13.9 Billion $2.3 Billion
Q1 2023 $ 13.2 Billion $2.3 Billion
Q4 2022 $ 13.1 Billion $1.5 Billion

View All

NVS Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q3 2024 $13.6 Billion $103.5 Billion $30.6 Billion $43.4 Billion
Q2 2024 $7.9 Billion $97.5 Billion $29.0 Billion $41.9 Billion
Q1 2024 $9.5 Billion $94.3 Billion $27.3 Billion $39.8 Billion
Q4 2023 $13.4 Billion $99.9 Billion $26.3 Billion $46.8 Billion
Q3 2023 $12.4 Billion $112.7 Billion $25.2 Billion $38.2 Billion
Q2 2023 $10.9 Billion $111.0 Billion $28.3 Billion $51.8 Billion
Q1 2023 $12.0 Billion $112.2 Billion $29.2 Billion $52.1 Billion
Q4 2022 $7.5 Billion $117.5 Billion $28.0 Billion $59.3 Billion

View All

NVS Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q3 2024 $6.0 Billion -$321.0 Million $5.7 Billion
Q2 2024 $4.1 Billion -$728.0 Million -$1.6 Billion
Q1 2024 $1.1 Billion -$1.2 Billion -$3.9 Billion
Q4 2023 $1.8 Billion -$783.0 Million $988.0 Million
Q3 2023 $4.7 Billion -$683.0 Million $1.5 Billion
Q2 2023 $2.6 Billion -$996.0 Million -$1.1 Billion
Q1 2023 $2.5 Billion -$470.0 Million $4.5 Billion
Q4 2022 $3.5 Billion -$647.0 Million -$1.2 Billion

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions